Councils - Chronic Thromboembolic Pulmonary Hypertension (CTEPH)



Scientific Council on Chronic Thromboembolic Pulmonary Hypertension



NOT A COUNCIL MEMBER?

Council membership is open to all ISHLT members. Joining is easy. Simply login to the ISHLT Members Only Website where you can update your membership profile and join any of the 12 Scientific Councils.



PAST COUNCIL MEETING:
Wednesday, April 5, 2017, 6:15 PM - 7:15 PM
in La Jolla AB of the Manchester Grand Hyatt Hotel, San Diego CA, USA, during the ISHLT 37th Annual Meeting and Scientific Sessions


CTEPH COUNCIL CREATION
After much deliberation, the ISHLT Board of Directors has approved the establishment of a separate CTEPH (chronic thromboembolic pulmonary hypertension) Council within the Society. The idea to create a separate Council was born out of complimentary goals from CTEPH expert members and ISHLT leadership to have a reliable international platform to discuss and engage multinational CTEPH experts in important domain projects, and for the ISHLT to engage the world-wide community and increase its membership. Among several other relevant points, some domain experts in the field of CTEPH who know the community best (especially from the surgical and interventional side of the discipline, who do not presently engage in the Society), have felt a strong need to have an independent platform separate from the PH council through which they can congregate and spend adequate time evaluating new therapies and establishing best practices. The ISHLT hopes to provide this international “home” for the CTEPH community. All interested ISHLT members are invite to join the CTEPH Council. The first Chair of the new CTEPH Council, Dr. William Auger from the University of California San Diego, has been appointed by the Board for a 2-year term. Forthcoming officers will be elected by the membership of the Council.

COUNCIL LEADERSHIP OPERATING BOARD
(Parentheses after name indicates year rotating off Board)

COUNCIL CHAIR:

William R. Auger, MD (2021)
UCSD Medical Center
San Diego, California, USA
bauger@ucsd.edu

Dr. Auger is currently a Professor of Clinical Medicine at the University of California, San Diego School of Medicine, and the director of UCSD's Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program. Having devoted 30 years to the management of CTEPH patients, his academic interests focus on the evaluation and treatment of pulmonary hypertension, particularly chronic thromboembolic disease and other large vessel pulmonary vascular disorders.

Dr. Auger accepted his faculty appointment at UC San Diego in 1989 after he completed a three-year pulmonary and critical care fellowship at the same university. Prior to this, he undertook a critical care fellowship at Ellis Hospital, an affiliate of Albany Medical Center in New York. He completed his Internal Medicine residency at Strong Memorial Hospital in Rochester, New York after earning his medical degree from the University of Rochester School of Medicine.

Dr. Auger is a member of the American Thoracic Society, the International CTEPH Association, the Pulmonary Vascular Research Institute, the Pulmonary Hypertension Association, the International Society for Heart and Lung Transplantation, the International Society on Thrombosis and Hemostasis, and a fellowship of the American College of Chest Physicians.




OPERATING BOARD CONSULTANT:

Marc De Perrot, MD (2018)
Toronto General Hospital
Toronto, CANADA
416-340-5549
marc.deperrot@uhn.ca

Bio coming soon...



BOARD OF DIRECTORS LIAISON:

Jason D. Christie, MD (2018)
University of Pennsylvania
Philadelphia, PA, USA
215-573-3209
jchristi@mail.med.upenn.edu

Jason D. Christie, M.D., M.S. is the Chief of the Pulmonary, Allergy, and Critical Care Division. He is Professor of Medicine in the Department of Medicine and Professor of Epidemiology in the Department of Biostatistics and Epidemiology at the University of Pennsylvania. He is a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. His career is focused on translational research studies of the risks, pathogenesis, treatment, and outcomes of acute lung injury (ALI) in the transplant and non-transplant human populations. Through leadership of the Center for Translational Lung Biology, Dr. Christie brings together clinicians, bench scientists, epidemiologists, and statisticians to build multidisciplinary research teams. His research integrates new knowledge generated from bench studies with epidemiology approaches in well-phenotyped, large human populations to generate new definitions of human syndromes, improved diagnostics and prognostics, and targeted therapy approaches in advanced lung diseases and critical illness.

Dr. Christie is the founder of the lung transplant outcomes group (LTOG), which is a multicentered cohort study the etiology and pathogenesis of acute lung injury following lung transplantation (termed primary graft dysfunction). This line of research is funded by multiple R01 grants from NHLBI; active LTOG research themes focus on the mechanisms of clinical factors that elevate PGD risk, including donor smoke exposure, recipient obesity and body composition, pulmonary hypertension, alterations in lung microbiome, and autoimmunity to lung collagens. His multidisciplinary lung transplant research focuses on genetics, innate immunity, regulatory T-cells, innate lymphoid cell (ILC) populations in the lung, ischemia reperfusion injury, inflammation, and autoimmunity.




EDUCATION WORKFORCE LEADER:

Manreet Kanwar, MD (2018)
Allegheny General Hospital
Pittsburgh, PA, USA
412-737-1667
mkanwar@wpahs.org

Bio coming soon...



COUNCIL LEADERSHIP OPERATING BOARD
(Parentheses after name indicates year rotating off Board)

COUNCIL CHAIR:

William R. Auger, MD (2021)
UCSD Medical Center
San Diego, California, USA
bauger@ucsd.edu

Dr. Auger is currently a Professor of Clinical Medicine at the University of California, San Diego School of Medicine, and the director of UCSD's Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program. Having devoted 30 years to the management of CTEPH patients, his academic interests focus on the evaluation and treatment of pulmonary hypertension, particularly chronic thromboembolic disease and other large vessel pulmonary vascular disorders.

Dr. Auger accepted his faculty appointment at UC San Diego in 1989 after he completed a three-year pulmonary and critical care fellowship at the same university. Prior to this, he undertook a critical care fellowship at Ellis Hospital, an affiliate of Albany Medical Center in New York. He completed his Internal Medicine residency at Strong Memorial Hospital in Rochester, New York after earning his medical degree from the University of Rochester School of Medicine.

Dr. Auger is a member of the American Thoracic Society, the International CTEPH Association, the Pulmonary Vascular Research Institute, the Pulmonary Hypertension Association, the International Society for Heart and Lung Transplantation, the International Society on Thrombosis and Hemostasis, and a fellowship of the American College of Chest Physicians.


OPERATING BOARD CONSULTANT:

Marc De Perrot, MD (2018)
Toronto General Hospital
Toronto, CANADA
416-340-5549
marc.deperrot@uhn.ca

Bio coming soon...

BOARD OF DIRECTORS LIAISON:

Jason D. Christie, MD (2018)
University of Pennsylvania
Philadelphia, PA, USA
215-573-3209
jchristi@mail.med.upenn.edu

Jason D. Christie, M.D., M.S. is the Chief of the Pulmonary, Allergy, and Critical Care Division. He is Professor of Medicine in the Department of Medicine and Professor of Epidemiology in the Department of Biostatistics and Epidemiology at the University of Pennsylvania. He is a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. His career is focused on translational research studies of the risks, pathogenesis, treatment, and outcomes of acute lung injury (ALI) in the transplant and non-transplant human populations. Through leadership of the Center for Translational Lung Biology, Dr. Christie brings together clinicians, bench scientists, epidemiologists, and statisticians to build multidisciplinary research teams. His research integrates new knowledge generated from bench studies with epidemiology approaches in well-phenotyped, large human populations to generate new definitions of human syndromes, improved diagnostics and prognostics, and targeted therapy approaches in advanced lung diseases and critical illness.

Dr. Christie is the founder of the lung transplant outcomes group (LTOG), which is a multicentered cohort study the etiology and pathogenesis of acute lung injury following lung transplantation (termed primary graft dysfunction). This line of research is funded by multiple R01 grants from NHLBI; active LTOG research themes focus on the mechanisms of clinical factors that elevate PGD risk, including donor smoke exposure, recipient obesity and body composition, pulmonary hypertension, alterations in lung microbiome, and autoimmunity to lung collagens. His multidisciplinary lung transplant research focuses on genetics, innate immunity, regulatory T-cells, innate lymphoid cell (ILC) populations in the lung, ischemia reperfusion injury, inflammation, and autoimmunity.



EDUCATION WORKFORCE LEADER:

Manreet Kanwar, MD (2018)
Allegheny General Hospital
Pittsburgh, PA, USA
412-737-1667
mkanwar@wpahs.org

Bio coming soon...

Text SizeIncrease Font SizeDecrease Font Size